Stockhead’s Year in Review video series is a yearly wrap up address from company leaders showcasing latest achievements, discoveries and developments of emerging ASX companies. …

It’s quarterlies season again as the ASX market announcements page becomes increasingly flooded with earnings lodgements. To save you the trouble of trudging through it…

Prescient’s PTX-100 Phase 1b study shows encouraging responses on a patient population that is notoriously difficult to treat. Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has revealed…

Prescient has unveiled the latest technology in its cancer-fighting portfolio CellPryme-A at the 7th annual CAR-TCR Summit in Boston, the world’s pre-eminent forum in the CAR…

There are many foundations and charities which aim to tackle health conditions through funding medical research to develop better treatment options, improve patient outcomes and…

Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. …

Prescient will join with the US’s largest cancer centre with the goal of creating best-in-class, adaptable CAR-T cell therapies to treat hematological malignancies. Clinical stage…

Clinical stage oncology company Prescient Therapeutics to progress its deep pipeline of innovative cancer therapies with capital raise. The company is looking to raise $8…